Results 161 to 170 of about 4,367 (184)
Some of the next articles are maybe not open access.
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
Clinical, Cosmetic and Investigational Dermatology, 2023Angelo Ruggiero +2 more
exaly
Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Skyrizi be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain ...
openaire +1 more source
Canada’s Drug Agency (CDA-AMC) recommends that Skyrizi be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain ...
openaire +1 more source
<p>Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis</p>
Journal of Inflammation Research, 2020Vidhatha Reddy +2 more
exaly
Risankizumab (Skyrizi) for Ulcerative Colitis
The Medical Letter on Drugs and TherapeuticsThe injectable interleukin (IL)-23 antagonist risankizumab-rzza (Skyrizi – Abbvie), previously approved by the FDA for treatment of Crohn’s disease (CD), has now been approved for treatment of moderately to severely active ulcerative colitis (UC) in adults. Risankizumab is the first IL-23 antagonist to be approved for treatment of both CD and UC. It is
openaire +2 more sources
A drug safety evaluation of risankizumab for psoriasis
Expert Opinion on Drug Safety, 2020Yi-Wei Huang
exaly